Table 3.
Comparison of metabolic changes by period and combination antiretroviral therapy regimen in the DGPLEAD study
| |
AZT+3TC+NVP (n = 58) |
D4T+3TC+NVP (n = 43) |
Other (n = 17) |
Global P** |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Baseline | End | P* | Baseline | End | P* | Baseline | End | P* | |
| HDL-c, mmol/L |
0.80 [0.61, 1.15] |
1.42 [1.17, 1.73] |
< 0.001 |
0.65 [0.34, 0.92] |
1.27 [1.02, 1.70] |
< 0.001 |
0.76 [0.57, 1.03] |
1.22 [0.96, 1.47] |
0.003 |
0.22 |
| LDL-c, mmol/L |
2.24 [1.76, 2.52] |
2.25 [2.00, 2.75] |
0.51 |
2.01 [1.44, 2.42] |
2.27 [1.81, 2.61] |
0.007 |
2.06 [1.71, 2.58] |
2.14 [1.84, 2.18] |
0.41 |
0.13 |
| TC, mmol/L |
3.59 [3.23, 3.99] |
4.00 [3.50, 4.68] |
< 0.001 |
3.46 [2.85, 4.08] |
4.13 [3.59, 4.58] |
< 0.001 |
3.40 [2.86, 3.87] |
3.50 [3.40, 3.73] |
0.77 |
0.04 |
| TC:HDL-c ratio |
4.54 [3.44, 5.84] |
2.78 [2.34, 3.49] |
< 0.001 |
5.32 [3.97, 8.93] |
3.08 [2.85, 3.94] |
< 0.001 |
4.34 [3.33, 5.82] |
2.73 [2.31, 3.00] |
0.001 |
0.36 |
| TG, mmol/L |
1.01 [0.86, 1.33] |
1.06 [0.70, 1.41] |
0.93 |
1.16 [1.88, 1.60] |
1.05 [0.85, 1.44] |
0.41 |
0.95 [0.77, 1.05] |
0.91 [0.68, 1.14] |
0.17 |
0.33 |
| Insulin, μU/mL |
3.00 [2.00, 5.00] |
6.70 [4.00, 12.50] |
< 0.001 |
3.00 [1.50, 5.00] |
7.65 [3.00, 13.45] |
< 0.001 |
2.60 [1.20, 5.90] |
4.65 [3.15, 9.70] |
0.07 |
0.18 |
| Glucose, mmol/L |
3.90 [3.60, 4.30] |
4.20 [3.60, 4.60] |
0.37 |
3.70 [3.40, 4.10] |
3.80 [3.20, 4.60] |
0.23 |
3.60 [3.00, 3.90] |
3.70 [3.50, 4.20] |
0.17 |
0.79 |
| HOMA-IR |
0.53 [0.33, 0.93] |
1.12 [0.62, 2.41] |
< 0.001 |
0.50 [0.28, 1.00] |
1.39 [0.49, 2.49] |
< 0.001 |
0.45 [0.16, 0.98] |
0.72 [0.49, 1.53] |
0.08 |
0.07 |
| BMI, kg/m2 |
20.1 [18.2, 21.5] |
20.3 [19.1, 22.2] |
0.001 |
19.6 [18.4, 21.1] |
20.6 [19.2, 22.4] |
< 0.001 |
19.4 [17.6, 22.4] |
20.1 [18.6, 22.3] |
0.49 |
0.26 |
| Weight, kg | 55.3 [51.0, 62.0] | 58.0 [53.5, 64.0] | 0.001 | 52.0 [46.0, 55.0] | 56.0 [47.0, 59.0] | < 0.001 | 53.0 [49.0, 60.5] | 55.0 [50.0, 57.0] | 0.49 | 0.30 |
Values are reported as median [25th percentile, 75th percentile].
* P-values obtained through Wilcoxon signed rank tests.
** P-values are from ANOVA with robust variance estimators comparing changes from baseline to 90 days after initiating cART and are adjusted for sex.
DGPLEAD, Diet, Genetic Polymorphisms in Lipid-Metabolizing Enzyme genes, and Antiretroviral Therapy-Related Dyslipidemia.